BERG is partnering with AstraZeneca to identify and evaluate novel targets and therapeutics to treat neurological disorders such as Parkinson’s disease. Under this research arrangement, AstraZeneca will initially provide BERG with its curated library of central nervous system (CNS) optimized fragments, and BERG will employ AstraZeneca’s fragment library to assist in discovering drug candidates for therapeutic development.